Matsumoto M, Yoshioka M, Togashi H, Ikeda T, Saito H
First Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 1996 May;353(6):621-9. doi: 10.1007/BF00167181.
The functional regulation by dopamine (DA) receptors of serotonin (5-HT) release from the rat hippocampus was investigated by use of in vivo microdialysis. Dialysate 5-HT levels were reduced by co-perfusion of 10 microM tetrodotoxin (TTX) and were elicited by K+ (60 and 120 mM) stimulation in a concentration-dependent manner. Local perfusion (10 microM) and peripheral administration (20 mg/kg, i.p.) of fluoxetine produced increases in 5-HT levels. These results indicate that the spontaneous 5-HT levels in the rat hippocampus can be used as indices of neuronal origin from the serotonergic nerve terminals. The nonselective dopamine (DA) receptor agonist apomorphine (1, 10 and 100 microM), when perfused through the probe over a period of 40 min, increased 5-HT release in a concentration-dependent manner. Apomorphine-induced (100 microM) increases in 5-HT release was abolished by pretreatment with the selective D2 receptor antagonist, S(-)-sulpiride (1 and 10 microM), but not prevented by pretreatment with the selective D1 receptor antagonist, R(+)-SCH-23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine) (1 microM). S(-)-Sulpiride and R(+)-SCH-23390 by themselves did not alter the spontaneous 5-HT levels. The 5-HT release was elevated by perfusion of the selective DA reuptake inhibitor GBR 12909 (1-[2-[bis(4-fluorophenyl) methoxy]ethyl]-4-[3-phenyl-propyl]piperazine) (1, 10 and 100 microM), indicating the possibility of not only exogenous but also endogenous DA-mediated facilitatory effects on 5-HT release in vivo. The 5-HT release was also elevated by perfused (+/-)-PPHT ((+/-)-2-(N-phenylethyl-N-propyl)-amino-5-hydroxytetralin) (1, 10 and 100 microM), the selective D2 receptor agonist, in a concentration-dependent manner. On the other hand, (+/-)-PPHT (100 microM) failed to increase 5-HT release in catecholamine (CA)-lesioned rats pretreated with 6-hydroxydopamine (6-OHDA)(200 micrograms/rat, i.c.v.). The (+/-)-PPHT-induced (100 microM) increase in 5-HT release was prevented not only by pretreatment with 10 microM S(-)-sulpiride but also by pretreatment with the alpha 2-adrenoceptor antagonist idazoxan (10 microM). These findings suggest that the functional regulation of 5-HT release via D2 receptors exists in the rat hippocampus. Furthermore our results indicate that the facilitatory effect of 5-HT release via D2 receptors may be mediated indirectly by noradrenergic neurons, but not mediated directly through D2 receptors located on serotonergic nerve terminals.
采用体内微透析技术研究了多巴胺(DA)受体对大鼠海马5-羟色胺(5-HT)释放的功能调节。用10微摩尔/升的河豚毒素(TTX)共同灌注可降低透析液中5-HT水平,而K+(60和120毫摩尔/升)刺激则以浓度依赖方式引发5-HT水平升高。局部灌注(10微摩尔/升)和外周给予(20毫克/千克,腹腔注射)氟西汀可使5-HT水平升高。这些结果表明,大鼠海马中自发的5-HT水平可作为5-羟色胺能神经末梢神经元起源的指标。非选择性多巴胺(DA)受体激动剂阿扑吗啡(1、10和100微摩尔/升)在40分钟内通过探针灌注时,以浓度依赖方式增加5-HT释放。阿扑吗啡诱导的(100微摩尔/升)5-HT释放增加可被选择性D2受体拮抗剂S(-)-舒必利(1和10微摩尔/升)预处理所消除,但不能被选择性D1受体拮抗剂R(+)-SCH-23390(R(+)-7-氯-8-羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓)(1微摩尔/升)预处理所阻止。S(-)-舒必利和R(+)-SCH-23390自身不会改变自发的5-HT水平。选择性DA再摄取抑制剂GBR 12909(1-[2-[双(4-氟苯基)甲氧基]乙基]-4-[3-苯基丙基]哌嗪)(1、10和100微摩尔/升)灌注可使5-HT释放升高,这表明体内外源性和内源性DA对5-HT释放均有促进作用。选择性D2受体激动剂(±)-PPHT((±)-2-(N-苯乙基-N-丙基)-氨基-5-羟基四氢萘)(1、10和100微摩尔/升)灌注也以浓度依赖方式使5-HT释放升高。另一方面,(±)-PPHT(100微摩尔/升)在用6-羟基多巴胺(6-OHDA)(200微克/大鼠,脑室内注射)预处理的儿茶酚胺(CA)损伤大鼠中未能增加5-HT释放。(±)-PPHT诱导的(100微摩尔/升)5-HT释放增加不仅可被10微摩尔/升S(-)-舒必利预处理所阻止,也可被α2-肾上腺素能受体拮抗剂咪唑克生(10微摩尔/升)预处理所阻止。这些发现表明,大鼠海马中存在通过D2受体对5-HT释放的功能调节。此外,我们的结果表明,通过D2受体对5-HT释放的促进作用可能由去甲肾上腺素能神经元间接介导,而非直接通过5-羟色胺能神经末梢上的D2受体介导。